News and Trends 3 Oct 2022 Poxel granted orphan drug designation for kidney disease treatment French biopharma company Poxel SA says the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to PXL770 for the treatment of patients with autosomal-dominant polycystic kidney disease (ADPKD). PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator – and is also a phase 2 ready ADPKD asset, subject […] October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jul 2021 Poxel’s Diabetes Drug Wins Japan Nod, But Competition Remains Fierce As French biotech Poxel marks the first market approval of its oral type 2 diabetes medication in Japan, eyes turn to the future of this drug and its rivals in Europe and the US. The fortunes of the Lyon-based Poxel have been boosted by the first-ever regulatory approval of its oral type 2 diabetes medication […] July 2, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Jul 2019 The Top 10 Biotechs You’ll Find in Lyon Lyon is one of the hotspots for biotech in Europe. Here are 10 of the most successful biotech companies in this beautiful French city. The second largest city in France (after Paris), Lyon boasts a thriving biotech ecosystem. In addition to the young startups and large biotech companies in the city, Lyon is also the […] July 10, 2019 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Apr 2019 French First-in-Class Diabetes Drug Nails Phase III Trial An oral first-in-class drug targeting the mitochondria, developed by the French biotech Poxel, has shown big potential for treating type 2 diabetes in a phase III trial in Japan. Poxel’s lead candidate drug imeglimin has taken a step closer to entering the huge market for diabetes type 2 treatments. In a phase III trial in […] April 9, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2018 French Biotech Takes its Oral Diabetes Drug to Phase III Update (13/03/2018): Poxel has started two more Phase III trials in Japan testing its drug for type 2 diabetes, imeglimin. This oral drug has shown potential to lower glucose levels thanks to a mechanism of action that targets the pancreas, the liver and muscles simultaneously. The new trials will confirm whether these effects are maintained in a larger […] March 13, 2018 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 12 Feb 2018 Healthcare-Biotech Partnership Pledges to Take its Type 2 Diabetes Treatment Worldwide Swiss pharma Roivant has given French biotech Poxel €28M upfront to get involved with the development and commercialization of imeglimin, a new treatment for metabolic disorders like type 2 diabetes. Poxel uses its expertise in metabolism to develop drugs for the treatment of disorders like type 2 diabetes. Its candidate imeglimin has caught the eye of […] February 12, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Stories We Didn’t Cover: Next Human CRISPR Trials by Intellia? Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. Amryt has taken out a loan from the European Investment Bank to fund […] December 9, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email